Sunday 22 December 2024

The Pharma Letter Podcast — Episode 26 — CRO sector surges in bio revolution

Biotechnology
Simon Wentworth
24 October 2023
episode26-large-podcast

More on this story...

Pharmaceutical
Two new hires at Asia-Pacific-focused CRO Novotech
13 October 2023
Biotechnology
Singaporean CRO Novotech appoints new chief medical officer
4 October 2023
Pharmaceutical
Growing CDMO appoints new president of Novasep business
19 October 2023
Pharmaceutical
Data show outsourcing growth set to continue in future
1 December 2023


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze